Sharekhan's research report on Divi’s Laboratories
Divis Laboratories Limited’s (Divis) quarterly performance was marginally below our expectation. Growth outlook intact, capex to weigh on margins in FY2020, no pending regulatory hurdles. We expect the company to a report sales/profit CAGR of 21%/18% over FY2019-FY2021.
Outlook
We maintain our Buy rating on the stock with marginally lowered PT of Rs. 1,800.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Divi’s Laboratories_19082019
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
